
Eupraxia Pharmaceuticals Inc
TSX:EPRX

Fundamental Analysis


Revenue & Expenses Breakdown
Eupraxia Pharmaceuticals Inc
Balance Sheet Decomposition
Eupraxia Pharmaceuticals Inc
Current Assets | 28.6m |
Cash & Short-Term Investments | 27.5m |
Receivables | 238.5k |
Other Current Assets | 913.3k |
Non-Current Assets | 626.8k |
PP&E | 546.5k |
Other Non-Current Assets | 80.3k |
Free Cash Flow Analysis
Eupraxia Pharmaceuticals Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Eupraxia Pharmaceuticals Inc
Revenue
|
0
CAD
|
Operating Expenses
|
-25.9m
CAD
|
Operating Income
|
-25.9m
CAD
|
Other Expenses
|
-364.2k
CAD
|
Net Income
|
-26.2m
CAD
|
EPRX Profitability Score
Profitability Due Diligence
Eupraxia Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Score
Eupraxia Pharmaceuticals Inc's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
EPRX Solvency Score
Solvency Due Diligence
Eupraxia Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Score
Eupraxia Pharmaceuticals Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPRX Price Targets Summary
Eupraxia Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
EPRX
is 11.22 CAD
with a low forecast of 9.09 CAD and a high forecast of 12.6 CAD.
Dividends
Current shareholder yield for EPRX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?